Consistent with prior studies of potential insulin glargine biosimilars, INSTRIDE 1 and INSTRIDE 2 were structured to assess immunogenicity of type 1 and type 2 diabetes patient populations independently [15]. This evidence concerns the gene INS and type 2 diabetes mellitus.